The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
NCT07272343 on ClinicalTrials.gov · last registry update 2026-04-02
Recruiting now, toward 100 participants. Its estimated completion date, 30 June 2026, has passed with no update to the record. Primary outcome, as filed: HbA1c. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P4
- Drug
- semaglutideWegovy, Ozempic, Rybelsus
- Sponsor
- Second Affiliated Hospital of Nanchang University
- Sponsor type
- Other
- Enrollment
- 100
- Started
- 2023-02-10
- Primary completion
- 2026-06-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
HbA1c
Conditions studied
Type 2 Diabetes Mellitus (T2DM) · Semaglutide · Caloric Restriction
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.